Skip to main content

Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720.

Publication ,  Journal Article
Baer, MR; George, SL; Sanford, BL; Mrózek, K; Kolitz, JE; Moore, JO; Stone, RM; Powell, BL; Caligiuri, MA; Bloomfield, CD; Larson, RA ...
Published in: Leukemia
May 2011

Untreated de novo (n=421) and secondary (n=189) acute myeloid leukemia (AML) patients ≥60 years received intensified chemotherapy, including daunorubicin 60 mg/m(2) and etoposide 100 mg/m(2) during days 1, 2, 3 with cytarabine 100 mg/m(2) during days 1-7, with a second induction if needed and one consolidation course with these drugs and doses for 2, 2 and 5 days, respectively. In all, 287 (47%) achieved complete remission (CR), 136 (22%) died and 187 (31%) were non-responders. CR rates were 27, 44 and 52% for complex karyotypes, rare aberrations and neither (P<0.001), 52 and 37% for de novo and secondary AML (P=0.003), and 53 and 42% for age 60-69 and ≥70 years (P=0.015). In multivariable analysis, CR predictors included non-complex/non-rare karyotypes (P<0.001), de novo AML (P<0.001), better performance status (PS) (P<0.001) and younger age (P=0.001). Disease-free (DFS) and overall (OS) survival medians were 6.8 (95% CI: 6.2, 7.8) and 7.2 (95% CI: 6.4, 8.6) months. In multivariable analysis, DFS was shorter for complex karyotypes (P<0.001) and increasing white blood count (WBC) (P<0.001) and age (P=0.038), and OS for complex karyotypes (P<0.001), increasing WBC (P=0.001) and age (P<0.001), poorer PS (P<0.001) and secondary AML (P=0.010). Outcomes and prognostic factors were similar to those in previous Cancer and Leukemia Group B studies.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Leukemia

DOI

EISSN

1476-5551

Publication Date

May 2011

Volume

25

Issue

5

Start / End Page

800 / 807

Location

England

Related Subject Headings

  • Treatment Outcome
  • Survival Rate
  • Remission Induction
  • Middle Aged
  • Male
  • Leukemia, Myeloid, Acute
  • Karyotyping
  • Immunology
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Baer, M. R., George, S. L., Sanford, B. L., Mrózek, K., Kolitz, J. E., Moore, J. O., … Cancer and Leukemia Group B, . (2011). Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. Leukemia, 25(5), 800–807. https://doi.org/10.1038/leu.2011.9
Baer, M. R., S. L. George, B. L. Sanford, K. Mrózek, J. E. Kolitz, J. O. Moore, R. M. Stone, et al. “Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720.Leukemia 25, no. 5 (May 2011): 800–807. https://doi.org/10.1038/leu.2011.9.
Baer MR, George SL, Sanford BL, Mrózek K, Kolitz JE, Moore JO, Stone RM, Powell BL, Caligiuri MA, Bloomfield CD, Larson RA, Cancer and Leukemia Group B. Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. Leukemia. 2011 May;25(5):800–807.

Published In

Leukemia

DOI

EISSN

1476-5551

Publication Date

May 2011

Volume

25

Issue

5

Start / End Page

800 / 807

Location

England

Related Subject Headings

  • Treatment Outcome
  • Survival Rate
  • Remission Induction
  • Middle Aged
  • Male
  • Leukemia, Myeloid, Acute
  • Karyotyping
  • Immunology
  • Humans
  • Female